A short history of diagnostic tests for von Willebrand disease: In memory of Barry Firkin (1930 to 2001) and Ted Zimmerman (1937 to 1988)

Seminars in Thrombosis and Hemostasis

Volumn 32, Issue 5, 2006, Pages 445-455

  Koutts, Jerry ^a  

^a WESTMEAD HOSPITAL   (Australia)

Author keywords

Diagnosis; History; Von Willebrand disease (vWD)

Indexed keywords

BLOOD CLOTTING FACTOR 8C; GLYCOPROTEIN IB; LIGAND; ORAL CONTRACEPTIVE AGENT; POLYMER; RISTOCETIN; THROMBOCYTE RECEPTOR; VON WILLEBRAND FACTOR;

ARTICLE; AUTOSOMAL RECESSIVE INHERITANCE; BINDING SITE; BLEEDING TENDENCY; CLINICAL FEATURE; DIAGNOSTIC ACCURACY; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC VALUE; DISEASE CLASSIFICATION; ENVIRONMENTAL FACTOR; EPIGENETICS; EPISTAXIS; GENE; GENETIC LINKAGE; HEREDITY; HISTORY OF MEDICINE; HUMAN; IMMUNOELECTROPHORESIS; IMMUNOPRECIPITATION; INHERITANCE; LABORATORY TEST; MENORRHAGIA; PENETRANCE; POSTPARTUM HEMORRHAGE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEFICIENCY; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN PURIFICATION; PROTEIN STRUCTURE; RECEPTOR BINDING; RELIABILITY; SKIN BRUISING; STRUCTURE ANALYSIS; SURGERY; SYMPTOM; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; TOOTH EXTRACTION; VON WILLEBRAND DISEASE; VWF GENE;

HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; LABORATORY TECHNIQUES AND PROCEDURES; PORTRAITS; VON WILLEBRAND DISEASE;

EID: 33746648143     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-947858     Document Type: Article

References (128)

1. von Willebrand AE. Hereditar pseudohemofili. Finska Laekaresaellsk Handl 1926;67:87-112
2. Duke WW. The pathogenesis of purpura hemorrhagica with special reference to the part played by blood platelets. Arch Intern Med 1912;10:445-469
3. Ivy AC, Nelson D, Bucher G. The standardization of certain factors in the cutaneous "venostasis bleeding time technique." J Lab Clin Med 1941;26:1812-1822
4. Borchgrevink CF. The haemostatic effect of normal platelets in haemophilia and factor V deficiency. Acta Med Scand 1961;170:378-383
5. Salzman EW. Measurement of platelet adhesiveness: a simple in vitro technique demonstrating an abnormality in von Willebrand's disease. J Lab Clin Med 1963;62:724-735
6. Bowie EJM, Owen CA Jr, Thompson JH Jr, et al. Platelet adhesiveness in von Willebrand's disease. Am J Clin Pathol 1969;52:69-77
7. Larrieu MJ, Caen JP, Meyer DO, et al. Congenital bleeding disorders with long bleeding time and normal platelet count. II. Von Willebrand's disease (report of thirty seven patients). Am J Med 1968;45:3S4-372
8. Rodgers RPC, Levin J. A critical reappraisal of the bleeding time. Semin Thromb Hemost 1990;16:1-20
9. Lind SE. The bleeding time does not predict surgical bleeding. Blood 1991;77:2547-2552
10. Howard MA, Firkin BG. Ristocetin: a new tool in the investigation of platelet aggregation. Thromb Diath Haemorrh 1971;26:362-369
11. Howard MA, Sawers RJ, Firkin BG. Ristocetin: a means of differentiating von Willebrand's disease into two groups. Blood 1973;41:687-690
12. Weiss HJ, Hoyer LW, Rickles FR, et al. Quantitative assay of a plasma factor, deficient in von Willebrand's disease, that is necessary for platelet aggregation. Relationship to factor VIII pro-coagulant activity and antigen content. J Clin Invest 1973;52:2708-2716
13. Jenkins CS, Meyer D, Dreyfus MD, et al. Von Willebrand factor and ristocetin. 1. Mechanism of ristocetin induced platelet aggregation. Br J Haematol 1974;28:561-578
14. Olson JD, Brockway WI, Fass DN. Evaluation of ristocetin-Willebrand factor assay and ristocetin induced platelet aggregation. Am J Clin Pathol 1975;63:210-218
15. Zimmerman TS, Ratnoff OD, Powell AE. Immunological differentiation of classical hemophilia (factor VIII deficiency) and von Willebrand's disease with observations on combined deficiencies of antihemophilic factor and proaccelerin (factor V) and an acquired anticoagulant against antihemophilic factor. J Clin Invest 1971;50:244-254
16. Zimmerman TS, Hoyer LW, Dickinson L, Edgington TS. Determination of the von Willebrand's disease antigen (factor VIII related antigen) in plasma by quantitative immunoelectrophoresis. J Lab Clin Med 1975;86:152-159
17. Peake IR, Bloom AL. The use of an immunoradiometric assay for FVIII related antigen in the study of atypical von Willebrand's disease. Thromb Res 1977;10:27-32
18. Sixma JJ, Wester J. The hemostatic plug. Semin Hematol 1977;14:265-299
19. Koutts J, Howard MA, Firkin BG. Factor VIII physiology and pathology in man. In: Brown E, ed. Progress in Hematology. XI. New York: Grune and Stratton; 1979:115-145
20. Zimmerman TS. Factor VIII/von Willebrand factor. Structure and function. Ann NY Acad Sci 1987;509:53-59
21. Vehar GA, Keyt B, Eaton D, et al. Structure of human factor VIII. Nature 1984;312:337-342
22. Ruggeri ZM, Zimmerman TS. Variant von Willebrand disease: characterization of two subtypes by analysis of multimeric composition of factor VIII/von Willebrand factor in plasma and platelets. J Clin Invest 1980;65:1318-1325
23. Siedlecki CA, Lestini J, Kottke-Marchant KK, et al. Shear dependent changes in the three dimensional structure of human von Willebrand factor. Blood 1996;88:2939-2950
24. Ruggeri ZM. Von Willebrand factor. J Clin Invest 1997;99: 559-564
25. Ginsburg D, Handin RI, Bonthron DT. Human von Willebrand factor (VWF): isolation of complementary DNA (cDNA) clones and chromosomal localisation. Science 1985;228:1401-1406
26. Sadler JE, Shelton-Inloes BB, Sorace JM, et al. Cloning and characterization of two cDNAs coding for human von Willebrand factor. Proc Natl Acad Sci USA 1985;82:6394-6398
27. Von Willebrand factor mutation database. Available at: http://www.vwf.group.shef.ac.uk/. Accessed on October 7, 2005
28. Ruggeri ZM. Von Willebrand factor, platelets and endothelial cell interactions. J Thromb Haemost 2003;1:1335-1342
29. Ozaki Y, Asazuma N, Suzuki I, et al. Platelet GP-IX-V dependent signalling. J Thromb Haemost 2005;3:1745-1751
30. Watson SP, Auger JM, McCarty OJT, et al. GPVI and integrin alphaIIbeta3 signaling in platelets. J Thromb Haemost 2005;3:1752-1762
31. Coller BS. Platelet GPIIb/IIIa antagonists: the first anti-integrin receptor therapeutics. J Clin Invest 1997;99:1467-1471
32. Ruggeri ZM. Old concepts and new developments in the study of platelet aggregation. J Clin Invest 2000;105:699-701
33. Nilsson IM. von Willebrand's disease from 1926-1983. Scand J Haematol 1984;33(suppl 40):21-43
34. Minot G. A familial hemorrhagic condition associated with a prolongation of the bleeding time. Am J Med Sci 1928; 175:301-306
35. Biggs R, Eveling J, Richards G. The assay of antihaemophilic-globulin activity. Br J Haematol 1955;1:20-24
36. Hardisty RM, Macpherson JC. A one stage factor VIII (antihaemophilic globulin) assay and its use on venous and capillary plasma. Thromb Death Haemorrh 1962;7:215-228
37. Alexander B, Goldstein R. Dual hemostatic defect in pseudohemophilia. J Clin Invest 1953;32:551 (abst)
38. Nilsson IM, Blombäck M, von Fränckel I. On an inherited autosomal haemorrhagic diathesis with antihaemophilic globulin (AHG) deficiency and prolonged bleeding time. Acta Med Scand 1957;159:35-37
39. Shulman J, Smith CH, Erlandson M, et al. Vascular hemophilia. A familial hemorrhagic disease in males and females characterized by combined antihemophilic globulin deficiency and vascular abnormalities. Pediatrics 1956;18: 347-361
40. Blackburn EK, Macfie JM, Monaghan JH, Page AP. Antihaemorphilic factor deficiency: capillary defects of von Willebrand type, and idiopathic thrombocytopenia occurring in one family. J Clin Path 1961;14:540-542
41. Nilsson IM, Blombäck M, von Blombäck B. Willebrand's disease in Sweden. Its pathogenesis and treatment. Acta Med Scand 1959;164:263-278
42. Cornu P, Larrieu MJ, Caen J, et al. Transfusion studies in von Willebrand's disease: effect on bleeding time and factor VIII. Br J Haematol 1963;9:189-202
43. Miller CH, Graham JB, Goldin LR, et al. Genetics of classic von Willebrand's disease. 1. Phenotypic variations within families. Blood 1979;54:117-136
44. Abildgaard CF, Suzuki Z, Harrison J, et al. Serial studies in von Willebrand's disease: variability versus "variants". Blood 1980;56:712-716
45. Born GVR. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1982;194:827-829
46. Grundy WE, Sinclair AC, Theriault RJ, et al. Ristocetin, antimicrobial properties. Antibiotics Ann 1956-7;1:687-698
47. Gangarosa EJ. Complications of ristocetin therapy. Lancet 1958;1:1179-1180
48. Herting RJ, Lees B, Zimmerman AJ, et al. Ristocetin-a statistical review of 333 cases. JAMA 1956-7;1:687-698
49. Clancy RL, Jenkins E, Firkin B. Qualitative platelet abnormalities in idiopathic thrombocytopaenic purpure. N Engl J Med 1972;286:622-626
50. Clancy R, Jenkins E, Firkin B. Platelet defects in infectious mononucleosis. BMJ 1971;4:646-648
51. Van der Weyden MB, Clancy RL, Howard MA, et al. Qualitative platelet defects with reduced life span in acute leukaemia. Aust N Z J Med 1972;4:339-345
52. Howard MA, Hutton RA, Hardisty RM. Hereditary giant platelet syndrome: a disorder of a new aspect of platelet function. Br Med J 1973;2:586-588
53. Sadler JE. for the Subcommittee on von Willebrand Factor of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. A revised classification of von Willebrand disease. Thromb Haemost 1994;71:520-525
54. Italian Working Group. Spectrum of von Willebrand's disease. A study of 100 cases. Br J Haematol 1977;35:101-112
55. Ruggeri ZM, Pareti FI, Mannucci PM, et al. Heightened interaction between platelets and factor VIII/von Willebrand factor in a new subtype of von Willebrand's disease. N Engl J Med 1980;302:1047-1051
56. Ware J, Dent JA, Azuma H, et al. Identification of a point mutation in type IIb von Willebrand disease illustrating the regulation of von Willebrand factor affinity for the platelet membrane glycoprotein Ib-IX receptor. Proc Natl Acad Sci USA 1991;88:2946-2950
57. Randi AM, Rabinowitz I, Mancuso DJ, et al. Molecular basis of von Willebrand disease type IIB. J Clin Invest 1991;87: 1220-1226
58. Cooney KA, Nichols WC, Bruck ME, et al. The molecular defect in type IIB von Willebrand disease. Identification of four potential missense mutations within the putative GpIb binding sequence. J Clin Invest 1991; 87:1227-1233
59. Takahashi H. Studies in the pathophysiology and treatment of von Willebrand's disease. IV. Mechanisms of increased ristocetin induced platelet aggregation in von Willebrand's disease. Thromb Res 1980;19:857-867
60. Miller JI, Castella A. Platelet type von Willebrand's disease: characterization of a new bleeding disorder. Blood 1982;60: 790-794
61. Weiss HJ, Meyer D, Rabinowitz R, et al. Pseudo-von Willebrand's disease. An intrinsic platelet defect with aggregation by unmodified human factor VIII/von Willebrand factor and enhanced absorbtion of its high molecular weight multimers. N Engl J Med 1982;306:326-333
62. Miller CH, Cunningham D, Lyle VA, et al. Mutation in the gene encoding the alpha chain of platelet glycoprotein Ib in platelet type von Willebrand's disease. Proc Natl Acad Sci USA 1991;88:4761-4765
63. Russell SD, Roth GJ. Pseudo-von Willebrand's disease: a mutation in the platelet glycoprotein Ib alpha gene associated with a hyperactive platelet receptor. Blood 1993;81: 1787-1791
64. Phillips DR, Jennings LK, Edwards HH. Identification of membrane proteins mediating the interaction of human platelets. J Cell Biol 1980;86:77-86
65. Coller BS, Peerschke EI, Scudder LE, et al. Studies with a murine monoclonal antibody that abolishes ristocetin induced binding of von Willebrand factor to platelets: additional evidence in support of GPIb as a platelet receptor for von Willebrand factor. Blood 1983;61:99-110
66. Nurden AJ, Caen JP. Specific roles for platelet surface glycoproteins in platelet function. Nature 1975;255:720-722
67. Clementson KJ, McGregor JL, James E, et al. Characterization of the platelet membrane glycoprotein abnormalities in Bernard Soulier syndrome and comparison with normal with by surface labelling techniques and high resolution two dimensional gel electrophoresis. J Clin Invest 1982;70:304-311
68. Fujimura Y, Titani K, Holland LZ, et al. von Willebrand factor: a reduced and alkylated 52/48 kDa fragment beginning at amino acid residue 449 contains the domain interacting with platelet glycoprotein Ib. J Biol Chem 1986;261:381-385
69. Read MS, Shermer RW, Brinkhous K. Venom coagglutin: an activator of platelet aggregation dependent on von Willebrand factor. Proc Natl Acad Sci USA 1978;75:4514-4518
70. Kirby EP. The agglutination of human platelets by bovine factor VIII. J Lab Clin Med 1982;100:963-976
71. Moake JL, Turner NA, Stathopoulos NA, et al. Involvement of large plasma von Willebrand factor (VWF) multimers and unusually large VWF forms derived from endothelial cells in shear stress induced platelet aggregation. J Clin Invest 1986;78:1456-1461
72. Ikeda Y, Handa M, Kawano K, et al. The role of von Willebrand factor and fibrinogen in platelet aggregation under shear stress. J Clin Invest 1991;87:1234-1240
73. Pasi KJ, Collins PW, Keeling DM, et al. von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organisation. Haemophilia 2004;10:218-231
74. Favaloro EJ, Koutts J. Laboratory assays for von Willebrand factor: relative contribution to the diagnosis of von Willebrand's disease. Pathology 1997;29:385-391
75. Favaloro EJ, Smith J, Petinos P, et al. On behalf of the RCPA quality assurance program (QAP) in haematology-haemostasis scientific advisory panel. Laboratory testing for von Willebrand's disease: an assessment of current diagnostic practice and efficacy by means of a multi-laboratory survey. Thromb Haemost 1999;82:1276-1282
76. Budde U, Drewke E, Mainusch K, et al. Laboratory diagnosis of congenital von Willebrand's disease. Semin Thromb Hemost 2002;28:173-190
77. Van Hoorelbeke K, Cauwenberghs N, Vandercasteele G, et al. A reliable von Willebrand factor: ristocetin co-factor enzyme linked immunoabsorbent assay to differentiate between type 1 and type 2 von Willebrand's disease. Semin Thromb Hemost 2002;28:161-166
78. Murdock PJ, Woodhams BJ, Mathews KB, et al. Von Willebrand factor activity detected in a monoclonal antibody based ELISA: an alternative to the ristocetin cofactor platelet agglutination assay for diagnostic use. Thromb Haemost 1997;78:1272-1277
79. Favaloro EJ, Grispo L, Exner T, et al. Development of a simple collagen based ELISA assay aids in the diagnosis of, and permits sensitive discrimination between type I and type II von Willebrand's disease. Blood Coagul Fibrinolysis 1991;2:285-291
80. van Mourik JA, Mochtar IA. Purification of human anti-haemophilic factor (factor VIII) by gel chromatography. Biochim Biophys Acta 1970;221:677-679
81. Hoyer IW, Shainoff JR. Factor VIII related protein circulates in human plasma as high molecular weight multimers. Blood 1980;55:1056-1059
82. Counts RB, Paskell SL, Elgee S. Disulfide bonds and the quaternary structure of factor VIII/von Willebrand factor. J Clin Invest 1978;62:702-709
83. Over J, Bouma BM, van Mourik JA, et al. Heterogeneity of human Factor VIII. I. Characterisation of factor VIII present in the supernatant of cryoprecipitate. J Lab Clin Med 1978;91:32-46
84. Sixma JJ, Over J, Bouma BN, et al. Predominance of normal low molecular weight forms of factor VIII in "variant" von Willebrand's disease. Thromb Res 1978;12:929-935
85. Gralnick HR, Williams SB, Morisato DK. Effect of multimeric structure of factor VIII/von Willebrand factor protein on binding to platelets. Blood 1981;58:387-397
86. Koutts J, Stott L, Sawers RJ. Variant pattern of von Willebrand's disease. Thomb Research 1974;5:557-564
87. Ruggeri ZM, Zimmerman TS. Von Willebrand factor and von Willebrand disease. Blood 1987;70:895-904
88. Holmberg L, Nilsson IM. Genetic variants of von Willebrand's disease. BMJ 1972;3:317-320
89. Firkin B, Firkin F, Stott L. von Willebrand's disease type B: a newly defined bleeding diathesis. Aust NZ J Med 1973; 3:225-229
90. Meyer D, Jenkins CSP, Dreyfus MD, et al. Willebrand factor and ristocetin. II. Relationship between Willebrand factor, Willebrand antigen and factor VIII activity. Br J Haematol 1974;28:579-599
91. Peake IR, Bloom AL, Giddings JC. Inherited variants of factor VIII related protein in von Willebrand's disease. N Engl J Med 1974;291:113-117
92. Peake IR, Liddel MB, Moodie P, et al. Severe type III von Willebrand's disease caused by deletions of exon42 of the von Willebrand factor gene: family studies that identify carriers of the condition and compound heterozygous individuals. Blood 1990;75:654-661
93. Schneppenheim R, Kreey S, Bergmann F, et al. Genetic heterogeneity of severe von Willebrand disease type III in the German population. Hum Genet 1994;94:640-652
94. Zhang ZP, Lindsedt M, Falk G, et al. Nonsense mutations of the von Willebrand gene in patients with von Willebrand disease type III and type I. Am J Hum Genet 1992;51: 850-858
95. Mannucci PM, Meyer D, Ruggeri ZM, et al. Precipitating antibodies in von Willebrand's disease. Nature 1976;262: 141-142
96. Sadler JE, Gralnick HR. Commentary: a new classification for von Willebrand's disease. Blood 1994;84:676-679
97. Howard MA, Salem HH, Thomas KB, et al. Variant von Willebrand's disease type B revisited. Blood 1982;60:1420-1428
98. Mannucci PM, Lombardi R, Castaman C, et al. Von Willebrand disease "Vicenza" with larger than normal (supra-normal) von Willebrand factor multimers. Blood 1988;71:65-70
99. Ciavarella G, Ciavarella N, Antoncecchi S, et al. High resolution analysis of von Willebrand factor multimeric composition defines a new variant of type 1 von Willebrand's disease with aberrant structure, but presence of all size multimers (type 1C). Blood 1985;66:1423-1429
100. Lyons SE, Bruck ME, Bowie EJ, et al. Impaired intracellular transport produced by a subset of Type IIA von Willebrand disease mutations. J Biol Chem 1992;267:4424-4430
101. Dent JA, Berkowitz SD, Ware J, et al. Identification of a cleavage site directing the immunochemical detection of molecular abnormalities in Type IIA von Willebrand factor. Proc Natl Acad Sci USA 1990;87:6306-6310
102. Schneppenheim R, Brassard J, Kray S, et al. Defective dimerization of von Willebrand factor subunits due to a Cys-Arg mutation in Type HD von Willebrand disease. Proc Natl Acad Sci USA 1996;93:3581-3586
103. Ginsburg D, Wagner DD. In: Hoffmann R, Benz EJ, Shattil SJ, et al, eds. Hematology: Basic Principles and Practice. 4th ed. Philadelphia, PA: Churchill Livingstone; 2005:2111-2114
104. Weiss HJ, Kochwa S. Molecular forms of antihemophilic globulins in plasma, cryoprecipitate and after thrombin activation. Br J Haematol 1970;18:89-100
105. Weiss HJ, Hoyer LW. Von Willebrand factor: dissociation from antihemophilic factor procoagulant activity. Science 1973;182:1149-1151
106. Owen WG, Wagner RH. Antihemophilic factor separation of an active fragment following dissociation by salts and detergents. Thromb Diath Haemorrh 1972;27:502-515
107. Zimmerman TS, Edgington TS. Factor VIII coagulant activity and factor VIII like antigen: independent molecular entities. J Exp Med 1973;138:1015-1020
108. Koutts J, Gude N, Firkin BG. The dynamic interrelationship between factor VIII and von Willebrand factor. Thromb Res 1976;8:533-541
109. Koutts J, Lavergne JM, Meyer D. Immunological evidence that human factor VIII is composed of two moieties. Br J Haematol 1977;37:415-427
110. Foster PA, Fulcher CA, Marti T, et al. A major factor VIII binding domain resides within the amino terminal 272 amino acid residues of von Willebrand factor. J Biol Chem 1987;262:8443-8446
111. Weiss HJ, Sussman II, Hoyer LW. Stabilization of factor VIII in plasma by the von Willebrand factor. J Clin Invest 1977;60:390-404
112. Nishino M, Girma J-P, Rothschild C, et al. New variant of von Willebrand's disease with defective binding to factor VIII. Blood 1989;74:1591-1599
113. Sadler JE. Von Willebrand disease type: a diagnosis in search of a disease. Blood 2003;101:2089-2093
114. Rodeghiero F. Willebrand disease: still an intriguing disorder in the era of molecular medicine. Haemophilia 2002; 8:292-300
115. Alperin JB. Estrogen and surgery in women with von Willebrand's disease. Am J Med 1982;73:367-371
116. Hoyer LW. The factor VIII complex: structure and function. Blood 1981;58:1-13
117. Gill JC, Endres-Brooks J, Bauer PJ, et al. The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood 1987;69:1691-1695
118. Mannucci PM, Lattuada A, Castaman G, et al. Heterogeneous phenotypes of platelet and plasma von Willebrand factor in obligatory heterozygotes for severe von Willebrand disease. Blood 1989;74:2433-2436
119. Mohlke KL, Ginsbrg D. Von Willebrand disease and quantitative variation in von Willebrand factor. J Lab Clin Med 1997;130:252-261
120. Werner EJ, Broxson EH, Tucker EL, et al. Prevalence of von Willebrand disease in children: a multicentre study. J Pediatr 1993;123:893-898
121. Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand's disease. Blood 1987;69:454-459
122. Castaman G, Eikenboom JCL, Bertina RM, et al. Inconsistency of association between type 1 von Willebrand disease phenotype and genotype in families identified in an epidemiological investigation. Thromb Haemost 1999;82: 1065-1070
123. Sadler JE, Mannucci PM, Berntrop E, et al. Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost 2000;84:160-174
124. Kouides PA. Females with von Willebrand's disease: 72 years as the silent majority. Haemophilia 1998;4:665-676
125. Kouides PA. Menorrhagia from a haematologist's point of view. Part 1: initial evaluation. Haemophilia 2002;8:330-338
126. Foster PA. The reproductive health of women with von Willebrand disease unresponsive to DDAVP-results of an international survey. Thromb Haemost 1995;74:784-790
127. Biron C, Mahieu B, Rochette P, et al. Preoperative screening for von Willebrand disease type 1: low yield and limited ability to predict bleeding. J Lab Clin Med 1999; 134:605-609
128. Coller BS, Schneiderham PI. In: Hoffman R, Benz EJ, Shattil SJ, et al, eds. Haematology: Basic Principles and Practice. 4th ed. Philadelphia, PA: Churchill Livingstone; 2005:1976-1982